Currently, there is a consensus among clinicians that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have a favorable efficacy in NSCLC patients with EGFR mutations, and some relevant research studies have suggested that the presence of EGFR mutations is a favorable prognostic marker [32]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.